Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population

Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population

 

Moses Galukande^1,&, Henry Wabinga², Florence Mirembe³, Charles Karamagi⁴, Alexzander Asea⁵

 

¹Department of Surgery, College of Health Sciences, Makerere University, Kampala, Uganda, ²Department of Pathology, College of Health Sciences, Makerere University, Kampala, Uganda, ³Department of Obstetrics and Gynecology, College of Health Sciences, Makerere University, Kampala, Uganda, ⁴Clinical Epidemiology Unit, College of Health Sciences, Makerere University, Kampala, Uganda, ⁵The Texas A & M Health Science Center College of Medicine, USA

 

 

^&Corresponding author
Moses Galukande, Department of Surgery, College of Health Sciences, Makerere University, Kampala, Uganda

 

 

 

 

Women in sub-Saharan Africa are experiencing a rapidly increasing burden of aggressive breast cancer [1-6]. In fact there is evidence suggesting an emerging epidemic of breast cancer in Africa [7, 8]. There is some evidence to suggest over re-presentation of unfavorable breast cancer phenotypes occurring mostly among pre-menopausal women in sub-Saharan Africa [2, 4, 9, 10]. Although the incidence of breast cancer is lower in developing than is in developed countries, in Uganda breast cancer incidence has nearly tripled in the past three decades [6] and there are more women with breast cancer below the age of 50 years. This is a much lower age compared to the western nations [6, 9, 11]. Similarly, in a recent British study black women presented at a younger age with a higher frequency of grade III and ER negative tumors. In addition there are poorer outcomes among black women than there are among white women with breast cancer [12]. Although, there are some data to explain these disparities [7, 8, 9, 11]. The reasons for the differences are not yet fully established, therefore more data are needed[13,14].Gene expression profiling tools and studies have identified breast cancer sub types and demonstrated the ability to predict clinical outcomes independent of other prognostic factors. These studies have led to the classification of breast carcinoma as luminal A, luminal B, human epidermal group factor receptor 2 (Her 2) - over expression and triple negative. These differ markedly in prognosis [12, 15, 16, 17]. Routine classification of breast cancer (based on hormonal receptor status) is practiced in most developed countries. In countries where severe resource constraints exist, the practice of profiling breast cancer by hormonal receptor status is not routinely done and therefore this characterization of breast cancers by molecular subtypes is not well documented. In the absence of hormonal status tests nearly all patients receive anti-hormonal therapy (tamoxifen) routinely. In Uganda the proportions of these molecular breast cancer subtypes are largely unknown. The aim of this study therefore was to determine the prevalence of molecular sub types among Ugandan women diagnosed with breast cancer.

 

Country Overview: Uganda is a land-locked country straddling the equator in eastern Africa. The country is 241,040 Km2 and currently has a population of over 32 million people [18]. Uganda is due to double its population (starting with 2,006 numbers) by 2037[19]. Almost one-third of the country lives in poverty (defined as living on less than US $1.25/day) [18]. A total of 85% of the population live in rural areas, and most of them work in the agriculture sector [20]. Uganda ranks at 143 among the 169 countries surveyed for the 2010 Human Development Index [21, 22]. The Ugandan Health system is developed with public and private providers, most health care is free and referral for cancer care is mostly to Mulago National referral and teaching hospital for the College of Health Sciences. The Makerere Pathology department is the only public unit providing free histopathology services in the country.

 

 

Design: Across sectional descriptive study; data were collected for the periods 2004-2007 and 2011- 2012.

 

Setting: The study was conducted at two institutions; Mulago hospital, the national referral hospital in Uganda with a 1500 bed capacity and with over 400 physicians and the Uganda Cancer Institute (UCI) located on the same campus as Mulago hospital. UCI is the only specialized public cancer treatment center in Uganda. Over the study period it was estimated that close to 500 patients could have presented to both institutions with invasive breast cancer.

 

Study population and Sampling procedure: Women with a histologically confirmed diagnosis of invasive breast cancer over the study period were included in the study. Those with insufficient clinical information were excluded from the analysis. The participants recruited prospectively had their samples obtained as core biopsies following the hospital standard protocol. The core biopsies were taken after infiltration with 2-3cc of 2% lignocaine but without US scans guidance. A BARD® magnum® device with 16G or 18G needles was used to take the core biopsies. Three cores were taken from each patient along with accompanying clinical details. All biopsy samples were fixed in 10% freshly prepared formalin. The fixed tissue samples were sent to the laboratory for histological analysis and immunochemistry. In addition, samples were retrieved from the specimen archives. Tumor sections were cut from the tissue blocks and a slide stained with haemotoxylin-eosin (H & E). A pathologist to confirm presence of cancer and histological grade reviewed each subject. Case notes were reviewed for additional information including age, residency (rural or urban) and stage. Slides were also stained for ER, PR and HER2/neu immediately after sectioning.

 

Evaluation of ER, PR & HER2/neu status and Quality Assurance: TNBC was defined as all ER, PR and HER2 receptors staining negative. HER2 positives were ER & PR negative and with HER2 positive staining. Luminal A was either ER or PR positive with a negative HER2. Luminal B was either ER positive /negative and or PR positive with a positive HER2. We used the quality assurance guidelines of the College of American Pathologists (CAP). The laboratory control tissue had a proven positive slide for each of the antibodies. A section of the positive and negative controls were used at every run of the day. Paraffin block specimens were cut into four sections and mounted on positively charged slides. The slides were paraffinized and rehydrated in xylene followed by graded alcohols, then washed in Tris buffered saline. The immunochemistry assays were performed using an immunostainer with antibodies and antigen unmasking. Appropriate negative controls for the immuno-staining were prepared by omitting the primary antibody step. The results were scored semi quantitatively using Reiner's four point scale based on intensity and percentage of IHC reaction [23], HER2 staining were evaluated according to manufacturer's instructions. Antibodies used were: ER (clone SP-I), ASR PR (clone Y85), ASR and HER2/neu (c-erbB-2), clone CB-11). (Cell marquee corporation, Rocklin, CA) ER/PR scoring system staining of <5% of tumor cell nuclei was considered negative. Both border line and overtly positive stains were considered positive. Her2/neu; negative was considered when no staining was observed or membrane staining was <10% of the tumor cells.

 

Evaluation of histopathological features: H & E staining was performed first to confirm diagnosis of invasive breast cancer before immunostaining. The histological type and grade were determined. An experienced consultant pathologist reviewed all the histological slides and the tumors were classified according to Nottingham modification of the Scorff Bloom Richardson criteria [24]. Based on histology, tumors were classified into the following groups: invasive ductal carcinoma (NoS), lobular, medullary, papillary, and colloid.

 

Data entry and analysis: A database was developed in SPSS version 17 for entry and analysis. Data on clinicopathological features among the two age groups >50 and <50 were compared using descriptive statistics.

 

Ethical considerations: The study was approved by the Makerere College of Health Sciences, School of Medicine Research and Ethics Committee and was duly registered with Uganda National Council of Science and Technology. All patients in the prospective arm gave written informed consent. The Ethics committee waived written consent for the retrospective arm. The juvenile in the study had consent given on her behalf by the parent.

 

 

A total of 226 cases were analysed. Out of the 144 patients screened for malignant disease, for the period 2010-2012, 34 posted non malignant histology results and were not included in the analysis. Of the estimated 383 breast cases that presented at both institutions during the 2004 -2007 period, 170 samples of confirmed breast cancer diagnosis (formalin fixed paraffin embedded tumor blocks) were available, 54 were excluded due to insufficient clinical data. In total 116 were included in the data analysis (Figure 1).

 

The mean age at presentation was 45 years (SD 14). TNBC constituted 34% of all cases (77/226), HER2+22% (49/226), Luminal A 38% (83/226) and Luminal B 5% (13/226). The majority of the women were premenopausal 152/226 (67%), considering 50year as the proxy for menopause. Women presented with stages III and IV disease were (73-88%). The predominant histological type was invasive ductal carcinoma (NoS) 93 -96% 2. One patient was a juvenile (13years old), the rest were 27 years and above (Table 1, Table 2).

 

 

We set out to determine the prevalence of molecular sub types of breast cancer among Ugandan women presenting at the national referral hospital and Uganda Cancer Institute. We found a 2 to 3 fold over representation of TNBC (34%) when compared to data from western countries where the prevalence of TNBC is 12-17% or less [25-27]. The histological grades were mostly grade III; the clinical stages at presentation were mostly III and IV (advanced disease). Her2 positive and TNBC tumors together constituted close to 60% of the breast cancer molecular sub types. The majority of women were 50years and below. Patients with HER2+ exhibit poor survival rates, more so in the absence of targeted therapies, which is the case in most resource poor settings.

 

Our study findings add to the existing evidence that breast cancer in sub-Saharan Africa is characterized by aggressive disease, advanced stage at presentation and with a significant proportion among young women under the age of 50 years [1, 4, 5, 7, 28-31]. There were no significant differences in the disease stage between the rural and the urban study participants, even though it is anticipated that the rural patients face significant travel and distance barriers to get to the diagnostic and treatment centers. HER2 and TNBC subtype represent the more unfavorable subtypes in as far as treatment outcomes are concerned. TNBC exhibits characteristics, which are quite distinct from other forms of breast cancer. TNBC presents as an aggressive disease, recurring and metastasizing more often than other kinds of breast cancers [27]. The occurrence of different prevalence rates of subtypes may not only suggest heterogeneity in oncogenesis, but also it part explains the differences in survival outcomes observed between the races (black Africans and Caucasians). Whereas, survival outcomes in resource rich countries are improved by new molecular target therapies such as Trastuzumab and lapatinib used in HER2+tumors, these therapies are hardly accessible by women in poor countries. Consistent with other studies we found that the ER negative breast cancer subtypes, which include TNBC and some of the HER2+, were associated with higher grade and higher proliferative capacity [32, 33]. The reasons for the relatively high TNBC and HER2 proportions are not yet fully understood. Some studies suggest that these disparities may be explained by genetic differences such as unidentified founder mutations in breast cancer [34, 35, 36]. Studies to explore gene mutation patterns may reveal the much needed clues [32, 37, 38]. The mean age in this study was 45 years at diagnosis, 10-15years earlier than in breast cancer populations in western industrialized countries [11,12,39]. The youngest participant was 13 years old. This 13-year old was an outlier, the next youngest woman with breast cancer was a 27-year old. The majority of patients were premenopausal taking 50years as a proxy for menopause [40, 41], the overwhelmingly large premenopausal proportions can be explained in part by the fact that the Ugandan population is largely young as described earlier in the study context and Uganda's life expectancy is at 53 years.

 

HER2 protein over expression is seen in 10% to 35% of human breast cancers and is associated with amplification of the gene in more than 96% of cases [25,26, 28, 29]. In this study the representation was 22%. Her2 over expression might be associated with reduced or even adverse response to anti-hormonal therapy. In addition to being a prognostic indicator Her2 over expression and amplification are important in determining treatment strategies, survival and response to treatment. The combined prevalence of TNBC and HER2+was close to 60%, it therefore follows that the routine (systematic) use of tamoxifen (anti hormonal therapy) without prior receptor status testing as it happens in most resource limited sub-Saharan countries [42], may not be beneficial to the majority of women under treatment. To many it is a source of false hope and a waste of meager resources. Endocrine therapy using tamoxifen, a selective ER modulator and aromatase inhibitors, which ablate peripheral estrogen synthesis, has been shown to substantially improve disease free survival. We now know that initial or acquired resistance to endocrine therapies may occur with tumors recurring as metastatic. The tumors in this study were mostly stages III & IV. Even though we didn't investigate endocrine resistance it is possible that there could be some endocrine resistance that developed as the disease progressed (to stage IV) [43,44]. These findings therefore call for a wider scale of data exploration perhaps from multiple sites and a rethink of how breast cancer is currently being managed in sub Saharan Africa.

 

Study limitations

 

Previously TNBC and basal like breast cancers were effectively synonymous [32,33], we now know that clinical micro assay and immuno-histochemical data show that this is not the case [25]. In this study we did not differentiate TNBC and basal like breast cancer because the majority of basal like cancers are also triple negative and the majority of TNBC (80%) also basal like [45]. We are aware that the high frequency of hormone receptor negativity in the retrospective arm may have been influenced to some extent by antigen degradation of archival materials [3, 8, 46]. To mitigate that influence high standards of laboratory testing processes were followed and the specimen storage period was short (less than 10 years). Hospital based studies may not be representative of the entire population, though in this case there was a fair representation of participants from all the four major regions of the country, giving a high level of confidence about the generalizability of these findings.

 

 

There was an over representation of unfavorable molecular sub types for breast cancer among this indigenous group of East African (mostly premenopausal) women. The empirical use of anti-hormonal therapy without prior receptor status testing should be reexamined. Further and larger studies are urgently required to elucidate the oncogenesis breast cancer sub types among black sub-Saharan African women.

 

 

The authors declare no competing interests

 

 

Moses Galukande conceived concept, collected data, participated in analysis and wrote the first draft. Henry Wabinga, Florence Mirembe, Charles Karamagi and Alexzander Asea contributed to writing and revising of drafts. All authors performed critical reviews of manuscript for intellectual content and approved the final manuscript.

 

 

Staff from: Uganda Cancer Institute, Mulago Hospital, Pathology department and Surgery department, College of Health Sciences, Makerere University. THRiVE and ADDRF for funding this study.

 

 

Table 1: Clinical and Biological tumor characteristics for the 226 Uganda Breast Cancer study participants

Table 2: Patient characteristics by Breast Molecular sub types, a Ugandan study 2013

Figure 1: Breast Cancer patients included in analysis

 

 

1. Awadelkarim D, Arizzi C, Elamin EO, Hamad HM, De Blasio P,Mekki SO, Osman I,BiunnoI,et al. Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: Implications for breast cancer in Africa. Histopathology. 2008;52(4): 444-456. PubMed | Google Scholar


2. Huo D,Ikpatt F,Khramtsov A,Dangou JM, Nanda R,Dignam J, Zhang B, et al. Population differences in breast cancer: Survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009;27(27): 4515-4521. PubMed | Google Scholar


3. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008;110(1): 183-188. PubMed | Google Scholar


4. Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: Evidence of a biologically different disease. Ann Surg Oncol. 2008;15: 1983-1988. PubMed | Google Scholar


5. Mbonde MP, Amir H, Schwartz-Albiez R,Akslen LA, Kitinya JN. Expression of estrogen and progesterone receptors in carcinomas of the female breast in Tanzania. Oncol Rep. 2000;7(2): 277-283. PubMed | Google Scholar


6. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing trends for Cancer incidence in Kampala, Uganda 1991-200 Int J Cancer. 2010; 126(5): 1187-1195. PubMed | Google Scholar


7. Lingwood RJ, Boyle P, Milburn A, Ngoma T, Arbuthnott J, McCaffrey R, Kerr SH, Kerr DJ. The challenge of cancer control in Africa. Nat Rev Cancer. 2008; 8(5): 398-403. PubMed | Google Scholar


8. Akarolo-Antony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res. 2010; 12(suppl 4): S. PubMed | Google Scholar


9. Gakwaya A, Kigula-Mugambe JB, Kavuma A, Luwaga A, Fualal J, Galukande M, Kanyike D. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer. 2008 Jul 8;99(1):63-7.. PubMed | Google Scholar


10. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African Women. AMPIS. 2008; 116(6): 515-25. PubMed | Google Scholar


11. Chu KC, Anderson WF. Rates for breast cancer characteristics by Oestrogen and Progesterone receptor status in the major racial/ethical groups. Breast Cancer Res Treat. 2002 Jun;74(3):199-211.. PubMed | Google Scholar


12. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British black women. Br J Cancer. 2008; 98(2): 277-281. PubMed | Google Scholar


13. Sayed S, Moloo Z, Bird P, Wasike R, Njoroge W, Karanu J, et al. Breast cancer diagnosis in a resource poor environment through collaborative multidisciplinary approach: the Kenyan experience. J Clin Pathol. 2013; 66(4): 307-11. PubMed | Google Scholar


14. Pang J, Toy KA,Griffith KA, Awuah B, Quayson S, Newman LA, Kleer GC. Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high Her2 expression. Breast Cancer Res Treat. 2012; 135(1): 59-66. PubMed | Google Scholar


15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumors. Nature. 2000; 406(6797): 747-752. PubMed | Google Scholar


16. Sorlie T, Perou CM, Tibshirani R, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguishes tumor sub classes with clinical implications. Proc Natl Acad Sci USA. 2001; 98(19):10869-74. PubMed | Google Scholar


17. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor sub types in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100(14):8418-23. PubMed | Google Scholar


18. Anonymous (2009) Data: Uganda (updated December 2010). The World Bank, Washington, DC Available at: http://data.world bank.org/country/Uganda/ Accessed February 13, 2011.


19. Anonymous (2007) The World Fact book (updated July 12, 2011). Central Intelligence Agency, Washington, DC. Available at: https://www.cia.gov/library/publications/the-world-factbook/geos/xx.html/. Accessed February 17, 2011.


20. Anonymous (2010) The Republic of Uganda Ministry of Finance, Planning, and Economic Development (2010) Millennium Development Goals Report for Uganda 2010. The Republic of Uganda, Kampala, Uganda. Google Scholar


21. Klugman J (2010) Human development report 2010. The real wealth of nations: pathways to human development. Palgrave Macmillan, New York.. Google Scholar


22. World Health Organization (2006) Global health observatory data repository. World Health Organization, Geneva Available at: http://apps.who.int/ghodata/?vid=20300/. Accessed February 15, 2011.


23. Reiner A, Neumeister B, Spora J et al. Immunocytochemical localization of oestrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 2000; 50: 7057-7061. PubMed | Google Scholar


24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, the value of histological grade in breast cancer experience from a large study with long term follow up. Histopathology. 1991; 19(5):401-10. PubMed | Google Scholar


25. Foulkes WD, Smith IE, Reis-Filho JS. Triple Negative Breast cancer. N Engl J Med. 2010; 363(20): 1938-48. PubMed | Google Scholar


26. Carey LA, Perou CM, Livasy CA, DresslerLG, Cowan D, Conway K, Karaca G, Troester MA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492-2502. PubMed | Google Scholar


27. Dent R, Hanna WM, Trudeau M, Raw-linson E, Sun P, Narod SA. Pattern of metastatic spread in triple negative breast cancer. Breast Cancer Res Treat. 2009; 115(2): 423 - 8. PubMed | Google Scholar


28. Wabinga HR, Parkin DM, Wabwire-Mangen F et al. Trends in Cancer incidence in Kyadondo County, Uganda 1060-1997. British Journal of Cancer. 2000 May; 82 (9): 1585-92. PubMed | Google Scholar


29. Ikpatt OF, Kuopio T, Ndoma-Eqba R, Collan Y. Breast Cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res. 2002; 22(5): 3005-12. PubMed | Google Scholar


30. Muthoni A, Miller AN. An explanation of rural and urban Kenyan women's knowledge and attitudes regarding Breast cancer and Breast cancer early detection measures. Health care for women International. 2010; 31(9): 801-816. PubMed | Google Scholar


31. Ssegwanyi J, Galukande M, Fualal J, Jombwe J. Prevalence of HIV/AIDS among Breast cancer patients and the associated clinico-pathological features. Annals of African Surgery. 2011; 8: 22-27. PubMed | Google Scholar


32. Otiriou C, Pusztai L. Gene expression signatures in breast cancer. N Eng J Medicine. 2009; 360(8):790-800. PubMed | Google Scholar


33. Kreike B, van Kouwenhove M, Horlings H et al. Gene expression profiling and histopathological characterization of triple negative/basal like breast carcinomas. Breast Cancer Res. 2007; 9(5):R65. PubMed | Google Scholar


34. Martin AM, Weber BL. Genetic and Hormonal risk factors. J Natl Cancer Inst. 2000; 92(14):1126-35. PubMed | Google Scholar


35. Shulman LP. Genetic and Genomic factors in Breast cancer: Management of the patient at High risk of breast cancer. Springer New York. 2013; PP 29-47. PubMed | Google Scholar


36. Gru AA, Allred DC. Molecular pathology of breast cancer in Molecular surgical pathology. Springer New York. 2013. PP 95-128. PubMed | Google Scholar


37. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al.Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell . 2012 ;149(5): 979-993. PubMed | Google Scholar


38. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, Prognostication and prediction: a retrospective of the last decade. J Pathol. 2010; 220(2):263-80. PubMed | Google Scholar


39. Fregene A, Newman LA. Breast Cancer in sub Saharan Africa: How does it relate to breast cancer in African-American women. Cancer. 2005; 103(8): 1540-50. PubMed | Google Scholar


40. Palmer JR, Rosenberg L, Wise LA, Horton NJ, Adams-Campbell LL. Onset of natural menopause in African American women. Am J Public Health. 2003 Feb;93(2):299-306.. PubMed | Google Scholar


41. Pathak RK, Parashar P. Age at Menopause and Associated Biosocial Factors of Health in Punjabi Women. The Open Anthropology Journal. 01/2010; 3:172-180. PubMed | Google Scholar


42. Madani Ly, Antoine M, Dembélé AK, Levy P, Rodenas A, et al. High Incidence of Triple-Negative Tumors in Sub-Saharan Africa: A Prospective Study of Breast Cancer Characteristics and Risk Factors in Malian Women Seen in a Bamako University Hospital. Oncology. 2012; 83(5):257-263. PubMed | Google Scholar


43. Dees C, Carey LA. Improving Endocrine Therapy for Breast Cancer: It's Not That Simple. Journal of Clinical Oncology. 2013; 31 (2): 171-173. PubMed | Google Scholar


44. Garcia-Becerra R, Santos N, Diaz L, Camacho J.Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance.. Int J Mol Sci . 2013;14(1): 108-145. PubMed | Google Scholar


45. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal like subtype of invasive breast cancer. Clinical Cancer Res. 2004; 10(6): 5367-74. PubMed | Google Scholar


46. Anderson BO, Shyyan R, Eniu A, Smith RA,Yip CH, Bese NS, Chow LW, Masood S,Ramsey SD, Carlson RW. Breast cancer inlimited-resource countries: on overview of the Breast Health Global Initiative 2005guidelines. Breast J. 2006; 12(suppl 1): 3-15. PubMed | Google Scholar